期刊文献+

HPLC-MS/MS法测定人血浆中多奈哌齐及其代谢物6-O-去甲基多奈哌齐浓度 被引量:1

Determination of donepoezil and its active metabolite 6-O-desmethyl donepezil in human plasma by HPLC-MS/MS method
原文传递
导出
摘要 目的:建立HPLC-MS/MS法测定血浆中多奈哌齐及其代谢物6-O-去甲基多奈哌齐浓度。方法:采用HPLC-MS/MS法,加入内标后,样品用二氯甲烷为萃取剂提取后进样,以Shisheido C18(100 mm×4.6mm,5μm)为色谱柱,甲醇-5 mmol·L-1醋酸铵-甲酸(80∶20∶0.05)为流动相,流速为0.2 mL·min-1,柱温为室温。离子化方式为电喷雾离子化,多反应离子监测。结果:多奈哌齐及6-O-去甲基多奈哌齐标准曲线线性范围分别为0.05~15 ng·mL-1和0.008~2.4 ng·mL-1,定量下限分别为0.05和0.008 ng·mL-1,二者日内RSD及日间RSD均<9%,方法回收率在96%~103%之间。稳定性考察试验,二者血药浓度变化率均在±15%内。结论:该方法简单,快速,可满足多奈哌齐及6-O-去甲基多奈哌齐血药浓度的测定及多奈哌齐药代动力学研究。 Objective :To develop a sensitive HPLC-MS/MS method for analyzing donepoezil and its active metabolite 6-O-desmethyl donepezil in human plasma, nethods:Donepoezil and 6-O-desmethyl donepezil in plas- ma samples were extracted with dichloromethane after addition of internal standard. The analytes went through Shis- heido C18 column (100 mm ×4.6 mm,5 μm) with mobile phase methanol-(5 mmol.L^-1) ammonium acetate-formic acid (80: 20:0.05 ) ;the flow rate was 0.2 mL.min^-1 ;the column temperature was ambient temperature ; ESI + was performed with MRM mode. Results:The calibration curves of donepoezil and 6-O-desmethyl donepezil were linear in the ranges of 0.05 - 15 ng-mL^-1 and 0. 008 -2.4 ng.mL^-1. The LLOQs of donepoezil and 6-O-desmethyl done- pezil in plasma were 0.05 and 0. 008 ng. mL^-1, respectively. Both the intra- and inter-day RSDs were less than 9% and the relative recovery was 96% - 103%. The concentration change of the samples in stability assay was within ± 15%. Conclusion:The method is simple and sensitive with good recovery and can be used in analyzing donepoezil and 6-O-desmethyl donepezil in plasma samples.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第16期1912-1915,共4页 Chinese Journal of New Drugs
关键词 多奈哌齐 代谢物 6-O-去甲基多奈哌齐 血药浓度 液质联用测定法 donepoezil metabolite 6-O-desmethyl donepezil plasma concentration HPLC-MS/MS
  • 相关文献

参考文献7

二级参考文献26

  • 1Pappa H,Farru R,Vilanova PO,et al.A new HPLC method to determine Donepezil hydrochloride in tablets[J].J Pharm Biomed Anal,2002,27 (1-2):177-82.
  • 2Yasui-Furukori N,Furuya R,Takahata T,et al.Determination of donepezil,an acetylcholinesterase inhibitor,in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection[J].J Chromatogr B Analyt Technol Biomed Life Sci,2002,768 (2):261-265.
  • 3Andrisano V,Bartolini M,Gotti R,et al.Determination of inhibitors'potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column[J].J Chromatogr B Biomed Sci Appl,2001,753(2):375-383.
  • 4Haginaka J,Seyama C.Determination of enantiomers of 1-benzyl4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020),a centrally acting acetylcholine esterase inhibitor,in plasma by liquid chromatography with fluorometric detection[J].J Chromatogr,1992,577(1):95-102.
  • 5Mihara M,Ohnishi A,Tomono Y,et al Pharmacokinetics of E2020,a new compound for Alzheimer's disease,in healthy male volunteers [J]. Int J Clin Pharmacol Ther Toxicol,1993,31(5):223-229.
  • 6Rho JP,Lipson LG. Focus on donepezil: a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease [J]. Formulary,1997,32(7):677-678.
  • 7Rogers SL,Doody RS,Mohs RC,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week,double-blind,placebo-controlled study [J]. Arch Intern Med,1998,158(9):1021-1031.
  • 8Rogers SL,Friedhoff LT. Pharmacokinetic and pharmacodymic profile of donepezil HCl following single oral doses [J]. Br J Clin Pharmacol,1998,46(Suppl 1):1-6.
  • 9Rogers SL,Cooper NM,Sukovaty R,et al. Pharmacodynamic profile of donepezil HCl following multiple oral doses [J]. Br J Clin Pharmacol,1998,46(Suppl 1):7-12.
  • 10Ohnishi A,Mihara M,Kamakura H,et al. Comparison of the pharmacokinetics of E2020,a new compound for Alzheimer's disease,in healthy young and elderly subjects [J]. J Clin Pharmacol,1993,33(11):1086-1091.

共引文献35

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部